Effects of combined sacubitril/valsartan and metoprolol succinate sustained release tablets on patients who suffer from the coronary heart disease with chronic heart failure

doi:10.3969/j.issn.1006-7795.2020.01.022

Abstract

Abstract: Objective This paper was to explored the clinical efficacy of combined sacubitril/valsartan and metoprolol succinate sustained release tablets on patients who had the coronary heart disease with chronic heart failure. Methods This paper selected patients who suffered from the coronary heart disease with chronic heart failure in The Third Affiliated Hospital of Henan University of Science and Technology and Zhengzhou Cardiovascular Hospital from September 2017 to September 2018 as the samples. Based on intergroup equilibrium, the samples were divided into treatment group (n=94) and control group (n=93) uniformly by hospitalization date, age, disease course, and gender. Metoprolol succinate sustained release tablets were applied in control group, while sacubitril/valsartan and metoprolol succinate sustained release tablets were combined in treatment group. The therapy for patients in both group lasted for 6 months. This paper compared the clinical efficacy and cardiac function index:maximum early filling speed (E), left ventricular ejection fraction (EF), maximum filling speed in late diastole (A), E/A, vascular endothelial function[plasma endothelin (ET), calcitonin gene-related peptide (CGRP), nitric oxide (NO)], between two groups before and after the therapy. Results The clinical efficacy in treatment group was 93.62% which was significantly 78.49% higher than that in control group. After the therapy, E, EF, E/A, CGRP, NO in treatment group were higher than those in control group, while A and ET were lower in treatment group (P<0.05). Conclusion The therapy of combined sacubitril/valsartan and metoprolol succinate sustained release tablets had significant efficacy on coronary heart disease and heart failure by improving the cardiac function.

Key words: sacubitril /valsartan, metoprolol succinate sustained release tablets, coronary heart disease with chronic heart failure, cardiac function

CLC Number:

Xia Yong, Zhang Jianqing, Wang Shaoxia, Chen Dan, Ji Jianmin. Effects of combined sacubitril/valsartan and metoprolol succinate sustained release tablets on patients who suffer from the coronary heart disease with chronic heart failure[J]. Journal of Capital Medical University, 2020, 41(1): 113-118.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2020.01.022

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2020/V41/I1/113

References

[1] Gomki P A, Ceholski D K, Hajjar R J. Ahered myocardial calcium cycling and energetics in heart failure-A rational approach for disease treatment[J]. Cell Metab, 2015, 21(2):183-194.
[2] Doehner W, Landmesser U. Xanthine oxidase and uric acid in cardiovascular disease:clinical impact and therapeutic options[J]. Semin Nephrol, 2011, 31(5):433-440.
[3] 赵世明.依那普利联合卡维地洛对慢性心力衰竭患者心功能、神经内分泌功能及血管内皮功能的影响研究[J].实用心脑肺血管病杂志, 2016, 24(3):19-22.
[4] Sarkar S, Koehler J. A dynamic risk score to identify increased risk for heart failure decompensation[J]. IEEE Trans Biomed Eng, 2013, 60(1):147-150.
[5] Yu S N, Lee M Y. Conditional mutual information-based feature selection for congestive heart failure recognition using heart rate variability[J].Comput Methods Programs Biomed, 2012, 108(1):299-309.
[6] 余新东,马中富,刘秀琴,等.冠心病患者血浆内皮素变化及其意义的Meta分析[J].标记免疫分析与临床, 2000,7(1):4-8.
[7] 裴建明,李红梅,牛国保,等.降钙素基因相关肽对心肌缺血时心脏功能的影响[J].心功能杂志, 1996,8(3):140-143.
[8] 章汝文,沈镀,孙巍巍,等.中枢一氧化氮对心血管作用的多样性研究[J].第二军医大学学报, 2012, 33(7):718-720.
[9] 张宇辉,张健. PARADIGM-HF研究设计解读[J].中国循环杂志, 2018, 33(2):200-202.
[10] McMurray J J, Packer M, Desai A S, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure[J].N Engl J Med, 2014, 371(11):993-1004.
[11] 董浩,门素珍,马丽娟,等.利钠肽系统与肾素-血管紧张素-醛固酮系统在心力衰竭中交互作用[J].现代生物医学进展, 2017, 17(13):2578-2581.
[12] 汪凛,陈礼学,夏旭辉,等.重组人脑利钠肽改善慢性心力衰竭利尿剂抵抗的作用及机制研究[J].疑难病杂志, 2015, 14(12):1211-1214, 1218.
[13] 李彦芬,陈春红,王占起,等.沙库巴曲缬沙坦对心衰患者血浆NE、AngⅡ、ALD和血清sCD40L、sICAM-1、sFas、sFasL、以及cTnI、MMP-9水平的影响研究[J].海南医学院学报, 2018, 24(6):665-668, 672.
[14] 唐娟.沙库巴曲缬沙坦联合比索洛尔治疗慢性心力衰竭的临床效果观察[J].临床合理用药杂志, 2018, 11(12):39-40.
[15] 董小伟,王红雷,来利红,等.沙库巴曲缬沙坦联合比索洛尔治疗慢性心力衰竭的临床研究[J].现代药物与临床, 2018, 33(11):2791-2794.
[16] 陈文文,刘燕琳,李振山,等.沙库巴曲缬沙坦在心衰治疗中的应用:从临床试验到真实世界[J].中国医院药学杂志, 2018, 38(21):2286-2290.
[17] 刘焰华,李枫,汪蛟龙,等.沙库巴曲缬沙坦治疗慢性心力衰竭[J].长春中医药大学学报, 2019, 35(3):457-460.
[18] Homma S, Miyanchi T, Sugishita V.Vasoconstrictor effects of endo-thelin-1 on myocardium microcirculation studied by the Langendorffperfusion method:differential sensitivities among microvessels[J]. Microvasc Res, 1992, 43(2):205-217.
[19] 刘洁,冯小平,王临光,等.冠心病患者血浆NO、ET、PGI2、TXB2的变化及银杏叶提取物对其的影响[J].放射免疫学杂志, 2010, 13(5):278.
[20] 高连如,刘国仗,赵云涛,等.基础内皮细胞衍生舒张因子水平在高血压发病学上的意[J].中华内科杂志, 1995,34(5):335-336.
[21] Girgis S I, Lappe D W,Stevenson J C,et al. Calcitonin gene-related peptide potevot vasodilator and major product of calcitonin gene[J]. Lancet, 1985, 2(8445):14-16.
[22] Kee Z, Kodji X, Brain S D. The role of calcitonin gene related peptide (CGRP) in neurogenic vasodilation and its cardioprotective effects[J]. Front Physiol, 2018, 9:1249.
[23] Yamamoto E, Kato T, Ozasa N, et al. Kyoto Congestive Heart Failure (KCHF) study:rationale and design[J]. ESC Heart Fail, 2017, 4(3):216-223.
[24] 杨玉雯,王德国,王新,等.老年心力衰竭患者血浆CGRP和ET-1水平的相关性分析[J].实用老年医学, 2005,19(4):187-189.
[25] 洪飞,汪磊.慢性心力衰竭患者血清CA125、hs-CRP和TNF-α水平及其与心功能的关系[J].中国医科大学学报,2017,46(9):787-790.
[26] 林洪.降钙素基因相关肽的表达调节及其心血管系统作用[J].中外医疗,2009, 28(13):157.
[27] Kusaka H, Sueta D, Koibuchi N, et al. LCZ696, Angiotensin II receptor-neprilysin inhibitor, ameliorates high-salt-induced hypertension and cardiovascular injury more than valsartan alone[J]. Am J Hypertens, 2015, 28(12):1409-1417.
[28] Wong P C, Guo J, Zhang A.The renal and cardiovascular effects of natriu-retic peptides[J]. Adv Physiol Educ, 2017, 41(2):179-185.
[29] 张辉,周文平,刘刚琼,等.沙库巴曲缬沙坦与依那普利对缺血型心肌病患者血流介导的血管扩张功能及颈动脉内中膜厚度的影响[J].临床心血管病杂志, 2018, 34(5):457-459.
[30] Felker G M, Ahmad T, Anstrom K J, et al. Rationale and design of the GUIDE-IT study:Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure[J]. JACC Heart Fail, 2014,2(5):457-465.